Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.75p +1.55% 49.00p 49.25p 50.50p 51.00p 48.25p 48.25p 216,779 09:30:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -6.3 -4.5 - 64.94

Immupharma Share Discussion Threads

Showing 9176 to 9200 of 9200 messages
Chat Pages: 368  367  366  365  364  363  362  361  360  359  358  357  Older
DateSubjectAuthorDiscuss
21/9/2017
09:46
Good news.it is a very safe drug. I wonder what the drop out is now. If it remains unchanged then the price should reflect this.
jpleight
21/9/2017
09:32
Safety profile one thing, but does it show any improvement over the placebo! Off course the whole point of the trial is to learn about the drug, dosage levels, etc., but this is still a long way from the open market!
bookbroker
21/9/2017
09:31
The only difference in this news is TM mentions they are seen increasing interest in the trial from physicians and lupus community's.Its just doesn't appear to be creating the same level of interest in the city.
best1467
21/9/2017
09:22
SK the Lanstead RNS would be a very welcome one!!
perfect pete
21/9/2017
08:23
I don't think it shows no drop outs. It shows a safety profile consistent with the Phase 2b, which was excellent.
sicilian_kan
21/9/2017
08:18
Very encouraging RNS. A few sad and miserables here who won't be satisfied at anything. The fact that no patient has dropped out and in the next couple of months all patients will reach 12 months, with safety record intact is something to be really cheerful about. So far so good ...
divinessence
21/9/2017
08:10
Bodes well methinks
chadders
21/9/2017
08:07
Two more RNSs this month?? Half yearly results; and Lanstead coming to an end?
sicilian_kan
21/9/2017
08:05
bookbroker, you are a negative poster and have been for a long time. You make statements like Zimmer the CSO "brings sweet FA to this company". That comment alone shows your ignorance and prejudice as well as the irrelevance of any opinion that you might express.
sicilian_kan
21/9/2017
08:03
lol they're damned if they do and damned if they don't. In the past, one of the biggest criticisms of the Immupharma BOD was a complete lack of communication. At the outset of the trial, they confirmed they would keep shareholders regularly updated and that's exactly what they're doing. No more and no less.
bermudashorts
21/9/2017
07:59
It is a bit pointless,except it shows that not one patient has dropped out and the trial is perfectly on course. Now needs a big fish to want to eventually take it on to commercialisation.
ewads
21/9/2017
07:58
This was a pointless statement, the interims are out on the 27/09., it states nothing more than a week will wait, it is concerning that the market has so little faith in the final outcome for such an important treatment!
bookbroker
21/9/2017
07:52
Basem. It is double blinded. They will not release efficacy data until q1 18. The rns is not pointless. It lets us know the safety record is still appearing to be v good and the length of time patients have been on lupuzor to date.
sicilian_kan
21/9/2017
07:45
Thanks sk, too early i wasnt thinking.
barriew
21/9/2017
07:44
A pointless RNS ? It doesn't state the effectiveness or am I missing something ? I stand corrected if necessary.
basem1
21/9/2017
07:43
Monty. If the trial is successful they should do a deal so no funding required. Luminoso will respond later
sicilian_kan
21/9/2017
07:39
If it comes to market, couple of years time, have they got the money until then, or another placing?
montyhedge
21/9/2017
07:32
Barriew it says all have passed 6 months. By October all will have passed 9 months and by January all wil have passed 12 months. The good news is all is on track and with what appears to be a safety record consistent with Phase2b which I note had a very low drop out rate for the active arm.
sicilian_kan
21/9/2017
07:22
Todays rns, isnt that the same news that we had in july before the conference? I would assume the majority of patients have passed 9 months now not 6 as stated, I tried to look on the link for the trial and said access forbidden.
barriew
21/9/2017
07:13
On track and sounding positive to me. Is my little punt going to bear fruit I wonder?
chadders
20/9/2017
18:02
lol - luninoso, what did you do to deserve the mark down? Agreed with SK I suppose.
bermudashorts
20/9/2017
17:15
Agree, SK. By the way did you see my 3679 post ?
luminoso
20/9/2017
16:38
Hmmm two tick downs in 10 minutes for saying that the risk reward ratio is fantastic. That's crazy. What price if the Phase 2b results for this dose are repeated? What price if the pooled results are repeated? In either case we are looking at multi bagging and in the former 10-15 times and a $bn valuation by close of the day thereafter? As for the risks, even taking a 50% CoS of a Phase 3 pass makes this very attractive compare to the upside potential. Yes it may fail. Yes I may lose significant chunks of my money. They key is to invest what I can afford to lose as part of a balanced portfolio. But the risk reward ratio does appear to be very very good at these prices.
sicilian_kan
20/9/2017
16:35
You can see still 2 derampers, as they vote down everything that gets posted for no reason,
barriew
20/9/2017
16:19
The risk reward ratio here is fantastic.
sicilian_kan
Chat Pages: 368  367  366  365  364  363  362  361  360  359  358  357  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170921 08:49:38